OncoMatch

OncoMatch/Clinical Trials/NCT05650749

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

Is NCT05650749 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies GPC2 CAR T cells for refractory neuroblastoma.

Phase 1RecruitingStephan Grupp MD PhDNCT05650749Data as of Jun 2026

Treatment: GPC2 CAR T cellsThis is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

GPC2 CAR T cells

Cancer type

Neuroblastoma

Disease stage

Required: Stage HIGH-RISK (COG), STAGE IVA, STAGE IVB (COG (Neuroblastoma), IRSS (Retinoblastoma))

Excluded: Stage STAGE III (RETINOBLASTOMA COHORT 1)

Metastatic disease required

high-risk neuroblastoma according to COG risk classification; metastatic retinoblastoma according to IRSS

Demographics

Ages ≥ 1

Lab requirements

Kidney function

age-adjusted serum creatinine ≤1.5 ULN for age

Liver function

Total bilirubin ≤ 1.5 x ULN (exception: ≤ 3 ULN for Gilbert's Disease); AST/ALT ≤ 2.5 ULN (≤ 5 x ULN with liver metastases)

Cardiac function

LVSF ≥28% or LVEF ≥ 50% confirmed by Echo, or adequate ventricular function documented by a scan or a cardiologist

Total bilirubin ≤ 1.5 x ULN (exception: ≤ 3 ULN for Gilbert's Disease); AST/ALT ≤ 2.5 ULN (≤ 5 x ULN with liver metastases); age-adjusted serum creatinine ≤1.5 ULN for age; LVSF ≥28% or LVEF ≥ 50% confirmed by Echo, or adequate ventricular function documented by a scan or a cardiologist

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Children's Hospital of Philadelphia · Philadelphia, Pennsylvania

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05650749 currently recruiting?

Yes, this trial is currently recruiting patients.

What disease stage is eligible?

Stage HIGH-RISK (COG) or STAGE IVA or STAGE IVB is required (metastatic disease required).

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify